18Fluorodeoxyglucose-Positron Emission Tomography in the Management of Patients With Suspected Pancreatic Cancer

Abstract

ObjectiveTo assess the accuracy and clinical impact of 18 fluorodeoxyglucose-positron emission tomography ( 18 FDG-PET) on the management of patients with suspected primary or recurrent pancreatic adenocarcinoma, and to assess the utility of 18 FDG-PET in grading tumor response to neoadjuvant chemoradiation. Summary Background DataThe diagnosis, staging, and treatment of pancreatic cancer remain difficult. Small primary tumors and hepatic metastases are often not well visualized by computed tomographic scanning (CT), resulting in a high incidence of nontherapeutic celiotomy and the frequent need for "blind resection." In addition, the distinction between local recurrence and nonspecific postoperative changes after resection can be difficult to ascertain on standard anatomic imaging. 18FDG-PET is a new imaging technique that takes advantage of increased glucose metabolism by tumor cells and may improve the diagnostic accuracy of preoperative studies for pancreatic adenocarcinoma. Methods Eighty-one18 FDG-PET scans were obtained in 70 patients undergoing evaluation for suspected primary or recurrent pancreatic adenocarcinoma. Of this group, 65 underwent evaluation for suspected primary pancreatic cancer. Nine patients underwent 18 FDG-PET imaging before and after neoadjuvant chemoradiation, and in eight patients 18 FDG-PET scans were performed for possible recurrent adenocarcinoma after resection. The 18 FDG-PET images were analyzed visually and semiquantitatively using the standard uptake ratio (SUR). The sensitivity and specificity of 18 FDG-PET and CT were determined for evaluation of the preoperative diagnosis of primary pancreatic carcinoma, and the impact of 18 FDG-PET on patient management was retrospectively assessed. ResultsAmong the 65 patients evaluated for primary tumor, 52 had proven pancreatic adenocarcinoma and 13 had benign lesions.18 FDG-PET had a higher sensitivity and specificity than CT in correctly diagnosing pancreatic carcinoma (92% and 85% vs. 65% and 62%). Eighteen patients (28%) had indeterminate or unrecognized pancreatic masses on CT clarified with 18 FDG-PET. Seven patients (11%) had indeterminate or unrecognized metastatic disease clarified with 18 FDG-PET. Overall, 18FDG-PET suggested potential alterations in clinical management in 28/65 patients (43%) with suspected primary pancreatic adenocarcinoma. Of the nine patients undergoing 18 FDG-PET imaging before and after neoadjuvant chemoradiation, four had evidence of tumor regression by PET, three showed stable disease, and two showed tumor progression. CT was unable to detect any response to neoadjuvant therapy in this group. Eight patients had 18 FDG-PET scans to evaluate suspected recurrent disease after resection. Four were noted to have new regions of 18 FDG-uptake in the resection bed; four had evidence of new hepatic metastases. All proved to have metastatic pancreatic adenocarcinoma. ConclusionsThese data confirm that 18 FDG-PET is useful in the evaluation of patients with suspected primary or recurrent pancreatic carcinoma.18...

Positron Emission Tomography for Basal Cell Carcinoma of the Head and Neck

“…Tumors tend to metabolize more glucose than normal tissue, thus mobilizing the imaging tracer and being detectable by the PET scanner. [1][2][3] This imaging has been proven to be effective for the staging, treatment planning, and monitoring of many extracutaneous cancers, including brain tumors, 4 colorectal cancer, 3,5,6 lung cancer, 7-13 pancreatic cancer, 14,15 breast cancer, [16][17][18] esophageal and gastric cancer, [19][20][21] bladder cancer, 22 and prostate cancer. 23,24 Use of the FDG-PET has also been successful in patients with metastatic melanoma for early detection of metastases, [25][26][27] accurate staging, [28][29][30][31][32][33] and close follow-up.…”

Preoperative Diagnostic Value of [18F] Fluorodeoxyglucose Positron Emission Tomography in Patients With Radioiodine-Negative Recurrent Well-Differentiated Thyroid Carcinoma

“…18 F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the detection and staging of different malignant tumors: soft tissue sarcomas; 3 cutaneous melanoma; 4 pancreatic, 5 breast, 6 colorectal, 7 esophageal, 8 head and neck, 9 and non-small-cell lung cancer; 10 neuroendocrine tumors;…”

18F-FDG activitiy PET/CT and CA-19.9 levels for the prediction of histopathological features and localization of peri- ampullary tumors

“…The pancreatic malignancy has variously been reported to be 2.2, 2.5, 2.8, and 3.0 (20,22,(26)(27)(28). In the present study, we used an SUV max threshold of 2.5 in our comparisons of SUV max with the histopathological features of periampullary tumors.…”